Kostakioti M., Hadjifrangiskou M., Cusumano C.K., Hannan T.J., Janetka J.W., & Hultgren S.J. (2012). “Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection.” Infect Immun. 2012 Aug;80(8):2826-34. doi: 10.1128/IAI.00283-12. Epub 2012 Jun 4. (Abstract)
Han Z., Pinkner J.S., Ford B., Chorell E., Crowley J.M., Cusumano C.K., Campbell S., Henderson J.P., Hultgren S.J., and Janetka J.W. (2012) “Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides.” J Med Chem. 2012 Apr 26;55(8):3945-59. doi: 10.1021/jm300165m. Epub 2012 Apr 13. (Abstract)
Cusumano C.K., Pinkner J.S., Han Z., Greene S.E., Ford B.A., Crowley J.R., Henderson J.P., Janetka J.W., and Hultgren S.J.
Treatment and prevention of urinary tract infection with orally active FimH inhibitors.
Sci Transl Med. 3(109):109ra115. doi: 10.1126/scitranslmed.3003021. (2011) (Abstract)
Ma C.X., Janetka J.W., and Piwnica-Worms H.
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.
Trends Mol Med. 17(2):88-96. doi: 10.1016/j.molmed.2010.10.009. (2011) (Abstract)
Oza V., Ashwell S., Brassil P., Breed J., Deng C., Ezhuthachan J., Haye H., Horn C., Janetka J., Lyne P., Newcombe N., Otterbien L., Pass M., Read J., Roswell S., Su M., Toader D., Yu D., Yu Y., Valentine A., Webborn P., White A., Zabludoff S., and Zheng X.
Discovery of a novel class of triazolones as checkpoint kinase inhibitors–hit to lead exploration.
Bioorg Med Chem Lett. 20(17):5133-8. doi: 10.1016/j.bmcl.2010.07.015. (2010) (Abstract)
Han, Z., Pinkner, J.S., Ford, B., Obermann, R., Nolan, W., Wildman, S.A., Hobbs, D., Ellenberger, T., Cusumano, C.K., Hultgren, S.J. and Janetka, J.W.
Structure-based drug design and optimization of mannoside bacterial FimH antagonists.
J Med Chem. 53(12):4779-92. doi: 10.1021/jm100438s. (2010) (Abstract)